Skip to main content

REVIEW article

Front. Med.
Sec. Dermatology
Volume 11 - 2024 | doi: 10.3389/fmed.2024.1474030

Canadian Consensus on Chlormethine gel use in Mycosis Fungoides-CTCL: literature review and real-world experience

Provisionally accepted
Ivan V. Litvinov Ivan V. Litvinov 1Mohannad Abu-Hilal Mohannad Abu-Hilal 2Raed Alhusayen Raed Alhusayen 3Bernard Delisle Bernard Delisle 4Jan Peter Dutz Jan Peter Dutz 5Sophie Helene Guenin Sophie Helene Guenin 6*Vincent Ho Vincent Ho 5Mark G. Kirchhof Mark G. Kirchhof 7Kevin Pehr Kevin Pehr 1David Roberge David Roberge 8
  • 1 McGill University, Montreal, Quebec, Canada
  • 2 McMaster University, Hamilton, Ontario, Canada
  • 3 DermCare Clinic, Mississauga, Canada
  • 4 Laval University, Quebec, Quebec, Canada
  • 5 University of British Columbia, Vancouver, British Columbia, Canada
  • 6 Icahn School of Medicine at Mount Sinai, New York, United States
  • 7 University of Ottawa, Ottawa, Ontario, Canada
  • 8 Montreal University, Montreal, Quebec, Canada

The final, formatted version of the article will be published soon.

    Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma (CTCL), representing the majority of all lymphomas arising in the skin. The disease treatment focuses on managing symptoms and preventing disease evolution. To date, there is no gold standard for MF-CTCL treatment. Chlormethine, a DNA alkylating agent, is a long-known treatment for CTCL. The new chlormethine 0.02% gel (CL-gel) formulation provides proven efficacy and ease of application, improving patient compliance and outcome. The current consensus paper and real-world experience with CL-gel in the treatment of early-stage MF-CTCL may help meet the unmet need for treatments in Canada. A modified Delphi process comprised a virtual meeting and an online follow-up. A panel of 9 board-certified dermatologists with expertise in cutaneous lymphoma and 1 radiation oncologist discussed the systematic literature review results, drew from clinical experience and the opinion of the panel to adopt and agree on five consensus statements. The panel shared real-world patient cases to illustrate the use of chlormethine gel in a variety of patients across Canada. Five real-world patient cases were provided to illustrate the panels' use of chlormethine gel.

    Keywords: chlormethine gel, Mycosis fungoide, CTCL, skin directed therapy (SDT), Canada

    Received: 31 Jul 2024; Accepted: 08 Nov 2024.

    Copyright: © 2024 Litvinov, Abu-Hilal, Alhusayen, Delisle, Dutz, Guenin, Ho, Kirchhof, Pehr and Roberge. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Sophie Helene Guenin, Icahn School of Medicine at Mount Sinai, New York, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.